Drug
Tipifarnib clinical trials
Also written Zarnestra, R115777 and NSC702818.
- studies test it
- 83
- open now
- 1
- in phase 3
- 4
- first study started
- 1999
Keep track of what changes. Save the tipifarnib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
82 studies that test it; most in 2002 (14)
| Year | Studies |
|---|---|
| 1999 | 3 |
| 2000 | 6 |
| 2001 | 9 |
| 2002 | 14 |
| 2003 | 7 |
| 2004 | 11 |
| 2005 | 6 |
| 2006 | 6 |
| 2007 | 5 |
| 2008 | 1 |
| 2011 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 33
- Phase 2
- 59
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 69
National Cancer Institute (NCI) (41) · Kura Oncology, Inc. (8) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Institut Claudius Regaud (2) · M.D. Anderson Cancer Center (2) · Abramson Cancer Center at Penn Medicine (2) · SWOG Cancer Research Network (2) · University Health Network, Toronto (2)
Often tested with
Tested in the same studies.
Bortezomib (5) · Gemcitabine (4) · Temozolomide (3) · Cytarabine (3) · Paclitaxel (2) · Doxorubicin (2) · Cyclophosphamide (2) · Erlotinib (2)
Studies
Open first, then newest update. How each study uses tipifarnib is read from its arms, and is right about nine times in ten.
Testing it · 83
- Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaRecruitingPhase 2Giselle ShollerNCT06540963Written as Tipifarnib
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04284774Written as Tipifarnib
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedPhase 1/2Kura Oncology, Inc.NCT04997902Written as Tipifarnib
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Tipifarnib
- Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedPhase 3National Cancer Institute (NCI)NCT00093470Written as Tipifarnib
- Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma MultiformeCompletedPhase 2Institut Claudius RegaudNCT00209989Written as Zarnestra
- Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionSTerminatedPhase 2Spanish Lung Cancer GroupNCT03496766Written as Tipifarnib
- Tipifarnib in Subjects With Myelodysplastic SyndromesTerminatedPhase 2Kura Oncology, Inc.NCT02779777Written as Tipifarnib
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaCompletedPhase 2Kura Oncology, Inc.NCT02807272Written as Tipifarnib
- Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsCompletedPhase 2Kura Oncology, Inc.NCT02383927Written as Tipifarnib
- Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyCompletedPhase 2Kura Oncology, Inc.NCT02464228Written as Tipifarnib
- Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyCompletedPhase 2Kura Oncology, Inc.NCT03719690Written as Tipifarnib
- Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesTerminatedPhase 1Kura Oncology, Inc.NCT04865159Written as Tipifarnib
- Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerWithdrawnPhase 1Kura Oncology, Inc.NCT05693090Written as Tipifarnib
- Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial CarcinomaStatus unknownPhase 2Samsung Medical CenterNCT02535650Written as tipifarnib
- Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00470301Written as tipifarnib
- Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT00026104Written as tipifarnib
- Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma MultiformeCompletedPhase 1/2M.D. Anderson Cancer CenterNCT00050986Written as R115777
- Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic CancerCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT00077519Written as tipifarnib
- Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedPhase 2National Cancer Institute (NCI)NCT00082888Written as Tipifarnib
See all 83 studies that test tipifarnib →
Given in every arm · 1 — tipifarnib is usual care beside what is tested
Codes
What other systems call tipifarnib · ClinicalTrials.gg INT004201
- MeSH (NLM) C402769tipifarnibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) MAT637500ATIPIFARNIBConfirmed FDA, NLM, Wikidata
- Wikidata Q7808830tipifarnibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1703TipifarnibOne source FDA
- DrugBank DB04960One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C402769 | tipifarnib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | MAT637500A | TIPIFARNIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7808830 | tipifarnib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1703 | Tipifarnib | One source FDA |
| DrugBank | DB04960 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.